However, recombinant BDNF failed to reverse motor decline or extend lifespan in both ALS mice and in a Phase III clinical ALS trial, possibly because the half-life of BDNF is too short 16. This evidence concerns the gene BDNF and amyotrophic lateral sclerosis.